NeoPharm CO., LTD. (092730) Fair Value & Analysis
Consumer Non-Cyclicals · KR · Market cap 272B KRW
Fair value as of: Jun 24, 2026
Analysis
NeoPharm CO., LTD. (092730) currently trades at 16,140 KRW, while our model-based Fair Value estimate is 64,590 KRW — implying the stock looks roughly 300.2% undervalued today. We read business quality at 95/100 (high quality), in the Consumer Non-Cyclicals sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
NeoPharm CO., LTD. manufactures and sells skin care products in South Korea. The company offers Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand; products for sensitive, dry, oily, or trouble-prone skin under the ZEROID brand; body moisturizers under the Derma-B brand; and sport care products for athletes under the MISSION ATHELETCARE brand. NeoPharm CO., LTD. was founded in 2000 and is headquartered in Daejeon, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is NeoPharm CO., LTD. (092730) undervalued?
What is the fair value of 092730?
What is the quality score of 092730?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.